Barzin A, Geurten C, Willems E, Baron F, Beguin Y, Servais S
Service d'Hématologie, CHU Liège, Belgique.
Service d'Hématologie-Oncologie pédiatrique, CHU Liège, Belgique.
Rev Med Liege. 2022 May;77(5-6):345-353.
Acute and/or chronic graft-versus-host disease (GVHD) is a serious complication after allogeneic hematopoietic stem cell transplantation (alloHSCT). It is a multisystemic inflammatory and/or fibrotic disease that occurs when the immune cells derived from the graft (and therefore originating from the donor) recognize recipient's healthy tissues as foreign and react against them. Acute GVHD is one of the main causes of non-relapse mortality after alloHSCT. Chronic GVHD can be very disabling in its severe form and can also be responsible for late mortality, mainly due to long-term immune deficiency and opportunistic infections. In contrast, GVHD can be associated with certain beneficial effects in patients transplanted for hematological malignancies, through simultaneous «graft versus tumour» positive effects. Therefore, one of the challenges of alloHSCT is the prevention and treatment of severe forms of GVHD without losing the beneficial anti-tumour effects of the graft.
急性和/或慢性移植物抗宿主病(GVHD)是异基因造血干细胞移植(alloHSCT)后的一种严重并发症。它是一种多系统炎症和/或纤维化疾病,当移植物来源的免疫细胞(因此源自供体)将受者的健康组织识别为外来物并对其产生反应时就会发生。急性GVHD是alloHSCT后非复发死亡率的主要原因之一。严重形式的慢性GVHD可能会导致严重功能障碍,也可能导致晚期死亡,主要是由于长期免疫缺陷和机会性感染。相比之下,对于因血液系统恶性肿瘤接受移植的患者,GVHD可能会产生某些有益影响,这是通过同时产生的“移植物抗肿瘤”积极作用实现的。因此,alloHSCT面临的挑战之一是预防和治疗严重形式的GVHD,同时又不丧失移植物有益的抗肿瘤作用。